SwePub
Sök i LIBRIS databas

  Utökad sökning

id:"swepub:oai:DiVA.org:uu-322794"
 

Sökning: id:"swepub:oai:DiVA.org:uu-322794" > Real-time Character...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00004093naa a2200481 4500
001oai:DiVA.org:uu-322794
003SwePub
008170614s2017 | |||||||||||000 ||eng|
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-3227942 URI
0247 a https://doi.org/10.3389/fimmu.2017.004552 DOI
040 a (SwePub)uu
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Bondza, Sinau Uppsala universitet,Medicinsk strålningsvetenskap,Ridgeview Instruments AB, Vange, Sweden4 aut0 (Swepub:uu)sinbo957
2451 0a Real-time Characterization of Antibody Binding to Receptors on Living Immune Cells
264 c 2017-04-24
264 1b Frontiers Media SA,c 2017
338 a electronic2 rdacarrier
520 a Understanding molecular interactions on immune cells is crucial for drug development to treat cancer and autoimmune diseases. When characterizing molecular interactions, the use of a relevant living model system is important, as processes such as receptor oligomerization and clustering can influence binding patterns. We developed a protocol to enable time-resolved analysis of ligand binding to receptors on living suspension cells. Different suspension cell lines and weakly adhering cells were tethered to Petri dishes with the help of a biomolecular anchor molecule, and antibody binding was analyzed using LigandTracer. The protocol and assay described in this report were used to characterize interactions involving eight cell lines. Experiments were successfully conducted in three different laboratories, demonstrating the robustness of the protocol. For various antibodies, affinities and kinetic rate constants were obtained for binding to CD20 on both Daudi and Ramos B-cells, the T-cell co-receptor CD3 on Jurkat cells, and the Fc gamma receptor CD32 on transfected HEK293 cells, respectively. Analyzing the binding of Rituximab to B-cells resulted in an affinity of 0.7-0.9 nM, which is similar to values reported previously for living B-cells. However, we observed a heterogeneous behavior for Rituximab interacting with B-cells, which to our knowledge has not been described previously. The understanding of complex interactions will be facilitated with the possibility to characterize binding processes in real-time on living immune cells. This provides the chance to broaden the understanding of how binding kinetics relate to biological function.
650 7a TEKNIK OCH TEKNOLOGIERx Industriell bioteknikx Medicinsk bioteknik0 (SwePub)209082 hsv//swe
650 7a ENGINEERING AND TECHNOLOGYx Industrial Biotechnologyx Medical Biotechnology0 (SwePub)209082 hsv//eng
653 a affinity
653 a kinetics
653 a therapeutic antibody
653 a B-cells
653 a T-cells
653 a CD20
653 a Fc gamma receptor
7001 a Foy, Eleanoru Univ Leeds, Leeds Inst Rheumat & Musculoskeletal Med, Leeds, W Yorkshire, England.4 aut
7001 a Brooks, Jonathanu Pfizer Inc, Cambridge, MA USA.4 aut
7001 a Andersson, Karl,d 1972-u Uppsala universitet,Medicinsk strålningsvetenskap,Ridgeview Instruments AB, Vange, Sweden4 aut0 (Swepub:uu)kaand227
7001 a Robinson, Jamesu Univ Leeds, Leeds Inst Rheumat & Musculoskeletal Med, Leeds, W Yorkshire, England.4 aut
7001 a Richalet, Pascaleu BioRevera LLC, Arlington, MA USA.4 aut
7001 a Buijs, Josu Uppsala universitet,Medicinsk strålningsvetenskap,Ridgeview Instruments AB, Vange, Sweden4 aut0 (Swepub:uu)josbu767
7102 a Uppsala universitetb Medicinsk strålningsvetenskap4 org
7730 t Frontiers in Immunologyd : Frontiers Media SAg 8q 8x 1664-3224
8564 u https://doi.org/10.3389/fimmu.2017.00455y Fulltext
8564 u https://uu.diva-portal.org/smash/get/diva2:1109452/FULLTEXT01.pdfx primaryx Raw objecty fulltext:print
8564 u https://doi.org/10.3389/fimmu.2017.00455
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-322794
8564 8u https://doi.org/10.3389/fimmu.2017.00455

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy